Breast Cancer — Microlearning Activity 3 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates

<p class="MsoNormal">Featuring an interview with Dr Priyanka Sharma<span class="normaltextrun">,</span> including the following topics:</p> <ul> <li>Endocrine therapy for hormone receptor-positive, HER2-negative high-risk localized breast cancer (0:00) <ul> <li>Johnston SR et al. monarchE: Primary overall survival (OS) results of adjuvant abemaciclib + endocrine therapy (ET) for HR+, HER2-, high-risk early breast cancer (EBC). ESMO 2025;<a href= "https://www.sciencedirect.com/science/article/pii/S0923753425047933" target="_blank" rel="noopener">Abstract LBA13</a>.</li> </ul> </li> <li>Durvalumab in combination with neoadjuvant chemotherapy for localized triple-negative breast cancer (TNBC) (3:25) <ul> <li>Loibl S et al. Durvalumab in combination with neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC) – Long-term analysis from the GeparNuevo trial. ESMO 2025;<a href= "https://www.annalsofoncology.org/article/S0923-7534(25)01641-2/fulltext" target="_blank" rel="noopen...